Gabelli Funds’s Cytokinetics CYTK Stock Holding History

Gabelli Funds’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.01M	Sell	11,909 -3,300	-22%	-$237K	0.01%	925
2026 Q1	$1M	Buy	15,209 +1,000	+7%	+$63.6K	0.01%	893
2025 Q4	$903K	Sell	14,209 -20,550	-59%	-$1.28M	0.01%	933
2025 Q3	$1.91M	Buy	34,759 +26,349	+313%	+$1.09M	0.01%	763
2025 Q2	$278K	Buy	8,410 +1,910	+29%	+$66.4K	﹤0.01%	1100
2025 Q1	$261K	Buy	6,500 +1,500	+30%	+$68.9K	﹤0.01%	979
2024 Q4	$235K	Sell	5,000 -400	-7%	-$20.8K	﹤0.01%	1000
2024 Q3	$285K	Buy	5,400 +400	+8%	+$22.3K	﹤0.01%	965
2024 Q2	$271K	Hold	5,000	–	–	﹤0.01%	958
2024 Q1	$351K	Buy	+5,000	New	+$387K	﹤0.01%	930

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gabelli Funds's CYTK Position: Q2 2026 in Review

Gabelli Funds reduced its Cytokinetics (CYTK) stake by 22% in Q2 2026, selling an estimated $237K and leaving 11,909 shares worth $1.01M. The position accounts for 0.01% of the portfolio, ranked #925.

Gabelli Funds first reported a position in CYTK in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.91M in Q3 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Gabelli Funds held 11,909 shares of Cytokinetics worth $1.01M as of Q2 2026.
Gabelli Funds sold 3,300 Cytokinetics shares in Q2 2026, an estimated $237K.
Cytokinetics made up 0.01% of Gabelli Funds's portfolio in Q2 2026, its #925 holding.
Gabelli Funds first reported a position in Cytokinetics in Q1 2024 and has held it in 10 quarters since.
Gabelli Funds's Cytokinetics position peaked at $1.91M in Q3 2025.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Gabelli Funds's 13F filing for Q2 2026, filed 12 Aug 2026.